Aytu BioPharma's revenue for the
three
months ended in Sep. 2024 was $16.57 Mil.
Its revenue for the trailing twelve months (TTM) ended in Sep. 2024 was $75.48 Mil.
Aytu BioPharma's Revenue per Share for the
three
months ended in Sep. 2024 was $1.82.
Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $12.43.
Warning Sign:
Aytu BioPharma Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Aytu BioPharma was -51.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -42.90% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -38.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Aytu BioPharma's highest 3-Year average Revenue per Share Growth Rate was -29.50% per year. The lowest was -59.90% per year. And the median was -39.40% per year.
Aytu BioPharma Revenue Historical Data
The historical data trend for Aytu BioPharma's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Aytu BioPharma's Revenue
For the Drug Manufacturers - Specialty & Generic subindustry, Aytu BioPharma's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aytu BioPharma's Revenue Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aytu BioPharma's Revenue distribution charts can be found below:
* The bar in red indicates where Aytu BioPharma's Revenue falls into.
Aytu BioPharma Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $75.48 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aytu BioPharma (LTS:0A8M) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Aytu BioPharma Revenue Related Terms
Thank you for viewing the detailed overview of Aytu BioPharma's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LTS:0A8M has been successfully added to your 